

NATIONAL ETHICS COMMITTEE FOR CLINICAL TRIALS OF GREECE

Questions and Answers

Opinion procedure of the Committee for clinical trials with medicinal products (Part II), clinical investigations of medical devices and performance studies of in vitro diagnostic medical devices

Version 2, 01.10.2026

This is a translation of the Greek text. In case of divergence, the Greek version prevails. Section identifiers correspond to the Greek version: A = Α, B = Β, C = Γ, D = Δ, E = Ε, F = ΣΤ.

History of changes

Version	Date	Content of the change
1	23.11.2022	Initial version. Questions 1 to 11 on Part II of clinical trials with medicinal products.
2	01.10.2026	Restructuring of the text into Parts A to F. Extension of the scope to clinical investigations of medical devices and to performance studies. Incorporation of the Committee's announcements of 2025 and 2026. Alignment of references with Government Gazette B' 230/22.01.2026. Addition of dossier completeness check points and of an index of announcements.

This document is dynamic in nature and is updated as required.

PART A

Introductory

A.1 What does this document cover?

It provides clarifications on the opinion procedure of the National Ethics Committee (the Committee) in respect of:

- clinical trials with medicinal products, as regards Part II of the application under Regulation (EU) No 536/2014;
- clinical investigations of medical devices under Regulation (EU) 2017/745;
- performance studies of in vitro diagnostic medical devices under Regulation (EU) 2017/746.

It does not cover Part I of the application, which is assessed by the National Organisation for Medicines, nor the procedure for signing the conduct agreement and for financial management (see A.4).

This document is an interpretative aid and does not replace the provisions of the above Regulations and of national law. In case of divergence, those provisions prevail.

A.2 Which Part II sections does the Committee assess?

The Committee assesses the Part II aspects of the dossier, whether the application is an initial application, a substantial modification or the addition of Greece as a Member State concerned. The sections are completed within CTIS only, in the following fields:

- Trial Sites
- Recruitment Arrangements
- Subject information and informed consent form
- Suitability of the investigator
- Suitability of the facilities
- Proof of insurance cover or indemnification
- Financial and other arrangements
- Compliance with National Requirements on Data Protection (section of the Form)
- Compliance with use of Biological samples

A.3 Does the Committee's Circular of 11.10.2019 still apply?

The Committee's Circular of 11.10.2019 was replaced by the Circular of 01.10.2026, following its publication on the Committee's official website.

A.4 Where are the conduct agreement and the financial documents submitted?

The signature of the conduct agreement and financial management are governed by Joint Ministerial Decision D3(a) 52922/2025 (Government Gazette B' 230/22.01.2026) and are carried out by the trial site, through its Clinical Trials Unit or the secretariat of the administration, and by the competent financial management body. The agreement templates A'1 to A'4 apply according to the type of study, together with the common Annexes B', C' and D'.

That procedure is not part of the Committee's assessment. For what is uploaded to the corresponding CTIS section, see C.7.

A.5 Where are questions on the general application of Regulation 536/2014 addressed?

To the Questions and Answers document and the other guidance documents of the European Commission, available in EudraLex, Volume 10. This document does not reproduce their content and refers to them where relevant.

PART B

Frequent matters

B.1 What are the language requirements?

Under Ministerial Decision G5a/59676/22.12.2016 (Government Gazette B' 4131), the application, the protocol, the information material addressed to subjects, the informed consent document, the labelling and the subject cards are submitted in Greek. The remaining elements of the dossier may be submitted in English.

The insurance certificate is accepted in either Greek or English.

For those elements of the dossier that are submitted in English, an official translation into Greek is to be provided whenever requested by the National Organisation for Medicines, in accordance with Article 3(1)(a) of Government Gazette B' 4131/2016.

Where translations of the consent documents into another language are required so that non-Greek-speaking subjects at Greek sites can understand them, these are also submitted. Where they are submitted later as a substantial modification, the translation is made from the approved Greek version.

B.2 What applies to the period of validity of the insurance policy?

Under Article 76 of Regulation (EU) No 536/2014 and Article 15 of Ministerial Decision G5a/59676/22.12.2016 (Government Gazette B' 4131), the sponsor is expressly obliged to keep adequate insurance cover fully in force, with a reputable insurance company established in a Member State of the European Union, for the conduct of the clinical study in Greece, throughout its duration. Where the insurance policy submitted expires before the completion of the study, the sponsor must ensure its timely and continuous renewal, with no gaps in cover. The updated insurance policies or certificates must be kept in the trial master file and made available immediately to the competent authorities and to the Committee upon request.

The cover concerns any injury or disability arising from participation in the study and, in the event of death or permanent incapacity for work, amounts to at least EUR 300,000.00 per subject.

B.3 What is provided to the subject free of charge?

Under Article 15 of Ministerial Decision G5a/59676/22.12.2016 (Government Gazette B' 4131), the sponsor provides free of charge, at no cost to the hospital, the subject, the subject's social security fund or private insurance:

- all investigational and auxiliary medicinal products and the medical devices used for their administration;
- all procedures required by the protocol, including the diagnosis and treatment of any adverse reactions;
- the cost of any unscheduled travel of subjects to and from the trial sites for safety reasons, and travel for special diagnostic tests at centres selected by the sponsor.

Any term to the contrary in the consent documents is deemed unwritten and invalid, even if it is not expressly identified by the National Organisation for Medicines or by the Committee.

B.4 Which financial benefits to subjects are acceptable?

Participation is voluntary. Reimbursement of the actual costs associated with participation, compensation for lost earnings or lost profit, and a reasonable lump sum for loss of time and for burden or inconvenience are accepted.

A distinct and equally acceptable category is a practical token of gratitude in the form of items, goods or services. Financial incentives intended to induce participation or continued participation, or to reward the subject's willingness, are not accepted.

For minors, persons lacking legal capacity and pregnant or breastfeeding women, only reimbursement of costs and the above compensation are permitted, together with a small token of appreciation subject to the Committee's approval.

Every benefit is documented in the trial file and is assessed as to its nature, amount, method of payment and justification.

Committee announcement of 22.07.2026 (see index F.1)

B.5 How may information be sought about subjects who withdraw?

Only through relatives or other persons designated by the subject. The designation is made in writing and separately, is recorded in the signed consent document, and the names are noted in the subject's medical file.

The use of a patient location service is accepted exceptionally, where cumulatively: it has not been possible to contact the subject despite the use of all available means; no persons have been designated, or contact with them has proved fruitless; there is separate written consent of the subject, not withdrawn; the subject has been informed in advance of the personal data that will be disclosed; and the reasons are adequately documented in the trial file.

That consent is given on a separate document, which states expressly that a refusal does not preclude participation. Beyond the civil registry, each online medium or social medium is listed expressly in a column and signed separately by the subject, so that the subject may choose which media to accept. Vague expressions such as "public records", "available online sources" or "for example" are not accepted.

Committee announcement of 03.07.2025 and decision of the 13th session of 20.01.2022 (see index F.1)

B.6 What applies to the future use of biological samples?

Consent is required at every stage: collection, processing, storage and transfer, as well as in respect of the data resulting from the analysis.

The original consent covers further or genetic analysis of samples already collected only where the consent document refers to future use and the prior information covers the possibility of further or genetic analysis, as well as the subject's right to know or not to know the findings, with the subject's view expressly recorded. Otherwise, prior specific consent is required.

Where the further analysis falls within the ongoing study and within its scientific scope, an amendment to the protocol is required. Where, by contrast, it serves a different purpose, a new protocol is required, documenting the purpose, its connection with the study and its necessity. The same applies after the end of the study, during the retention period of the samples.

Further processing of the personal data resulting from the analysis, for purposes other than the original ones, is examined under Regulation (EU) 2016/679 and the relevant national legislation.

Committee announcement of 05.05.2025 (see index F.1)

B.7 What applies to impartial witnesses?

Under Article 9 of Ministerial Decision G5a/59676/22.12.2016 (Government Gazette B' 4131), the witness must have legal capacity and must not be connected in any way with the clinical trial. More specifically, as regards impartial witnesses:

- Where the subject is deaf or unable to speak, at least one witness is present throughout the process and co-signs the information document and the consent document.
- Where the subject is unable to write or to read, both documents are signed by the designated member of the research team and by two witnesses.
- Where consent is recorded through appropriate alternative means, at least one witness is present and co-signs.

In all other cases no witness is required. The Committee nevertheless recommends that name and signature fields for witnesses be provided in the consent document as a precaution, so that a fresh submission is not needed should one of the above situations arise.

B.8 What applies to minors and to persons lacking legal capacity?

Article 10 of Ministerial Decision G5a/59676/22.12.2016 (Government Gazette B' 4131) determines, for Greece, which persons consent as legally designated representatives within the meaning of the Regulation, separately for minors and for persons lacking legal capacity.

Minors: For the participation of minors, information material is prepared that is appropriate to their age and to their cognitive and developmental level, distinct from the documents signed by the parents or legal representatives, and differentiated by age group. As soon as a minor acquires, under national law, the capacity to consent, a separate information and consent document is provided, so that continued participation rests on the minor's own understanding and voluntary agreement.

See the European Commission's recommendation paper on frequent issues identified during the assessment of Parts I and II, and question 9.4 of the Questions and Answers document in EudraLex, Volume 10.

Under Article 10 of Ministerial Decision G5a/59676/22.12.2016 (Government Gazette B' 4131), in addition to Article 32 of the Regulation, the written consent of the minor is also obtained, following information given in language the minor understands and to the extent the minor is able to understand, by investigators or team members trained or experienced in working with children. That written consent is in every case necessary for minors who have completed their tenth year. A minor's express wish to refuse or to withdraw is binding.

The written and signed consent is required in a separate ICF of both parents exercising parental care is also required or, where the minor is under guardianship, of the guardian appointed by the court. Where parental care of one parent has ceased, or that parent is demonstrably unable to exercise it, the other parent consents alone, supported by a solemn declaration setting out the factual grounds. In case of disagreement, the court decides.

Persons lacking or with limited legal capacity: For the participation of a person under judicial assistance by reason of a mental or intellectual disorder, prodigality, drug addiction or alcoholism, and subject to Articles 29(2) and 31 of the Regulation, the written consent of that person is obtained where and to the extent that he or she is able to understand. An express wish to refuse or to withdraw is binding.

The written and signed consent of the definitive judicial assistant appointed by the court and exercising care is also required, where the assistance is full and deprivative, or partial or auxiliary on the above grounds. That consent expresses the presumed will of the subject and may be withdrawn at any time, without adverse consequences for the subject.

In all other respects the provisions of the Civil Code and of Regulation (EU) No 536/2014 apply.

B.9 What applies to clinical studies in emergency situations?

Enrolment takes place in accordance with the conditions, which apply cumulatively, of Article 35 of Regulation (EU) No 536/2014.

Under Article 12 of Ministerial Decision G5a/59676/22.12.2016 (Government Gazette B' 4131), where Article 35 of the Regulation refers to the legally designated representative of the patient, and for the purposes of that Article only, the following are also to be understood as such, in addition to the cases of minors and of persons lacking or with limited legal capacity: the spouse, the partner under a cohabitation agreement, the adult descendants or ascendants of the patient, and the patient's siblings.

Consent is obtained, following information, from whichever of those persons can give it soonest. No strict order of priority applies.

B.10 Do documents uploaded to CTIS need to be signed?

See EudraLex, Volume 10, Chapter V, Questions and Answers on Regulation (EU) No 536/2014, question 1.4 (8). Note that the site suitability document is submitted signed by the Principal Investigator in all cases (see C.5), whereas, in the financial arrangements section, the research team documents uploaded there need not bear signatures (see C.7).

PART C

Clinical trials with medicinal products: Part II of the application

C.1 Trial Sites

The information on the trial sites of the clinical trial is entered in CTIS, together with, in accordance with paragraph 14 of Article 2 of Government Gazette B' 4131/2016, the details of the sites and the names and specialties of the Principal Investigators. Trial site: Clinical trials are conducted exclusively in hospitals (public hospitals or private clinics) which have the building and material infrastructure necessary to ensure compliance with Regulation (EU) No 536/2014 and adherence to the rules of Good Clinical Practice. The departments of the trial sites are identified consistently in all submitted documents (curricula vitae, declarations of interest, insurance certificate, financial documents). One Principal Investigator is designated per trial site: Under Article 2 of Regulation (EU) No 536/2014 the Principal Investigator is the investigator responsible for leading the team of investigators at the site, and responsibility for subject safety and data integrity is personal. The designation of two equal Principal Investigators at the same site is not accepted.

C.2 Recruitment Arrangements

It is recommended that the harmonised recruitment and consent procedure template published in EudraLex, Volume 10, Chapter 1 be used, duly completed in English.

Note that version 2.0 of the harmonised template, which was developed by MedEthicsEU and endorsed by CTAG, applies to all new Part II submissions from 1 September 2026.

Supporting documents bear at least one identifier of the study (title, EU CT number or protocol code), together with a version number and date.

In the template, sections 1, 2 and 5 are completed in full; sections 3 and 4, where they do not apply, are deleted or marked as not applicable.

Links and QR codes pointing to websites are not accepted, because website content can change without any possibility of tracking those changes. Placement on social media is likewise not permitted. As to the other recruitment rules, the Committee's circular applies.

C.3 Subject information and informed consent documents

The following are uploaded to the section "Subject information and informed consent form":

- all informed consent documents, in Greek, and any official translations of them (see B.1);
- the subject card, in Greek;
- any other document or material for subjects, their relatives or carers, given before or at the time of signature of the consent document.

Where a document is amended, the final version is uploaded both in clean form and with changes marked against the previous version.

Questionnaires relating to the endpoints of the trial are submitted with the protocol, in Part I of the dossier.

The title "Έντυπο Συναίνεσης μετά από Ενημέρωση" (Informed Consent Document) is stated in the title of the document and in the header or footer.

The name, version number and date of the document must be identical across CTIS, the first page and the header or footer. The Greek title of the study, the protocol code and the EU CT number are stated. Pages are numbered in the format "1 of X".

As to content, see also B.2 to B.9.

C.4 Suitability of the investigator

For each trial site:

- a short curriculum vitae of the Principal Investigator, referring to the current position and to training in ICH-GCP (R3); the "Investigator Curriculum Vitae" template in EudraLex, Volume 10, Chapter 1 is recommended, completed in English;
- a declaration of interest of the Principal Investigator; the "Declaration of Interest" template in EudraLex, Volume 10, Chapter 1 is recommended, completed in English and referring to the EU CT number.
- for Phase I studies a valid Advanced Life Support (ALS) training certificate of the Principal Investigator.

C.5 Suitability of the facilities

It is recommended that the "Site Suitability Template" published in EudraLex, Volume 10, Chapter 1 be used, completed in English and signed by the Principal Investigator in all cases. All its sections are completed, including the detailed description of suitability.

C.6 Proof of insurance cover or indemnification

Under Article 15 of Ministerial Decision G5a/59676/22.12.2016 (Government Gazette B' 4131), the sponsor must have concluded and must keep in force an insurance contract with a reputable insurance company established in a Member State of the European Union, covering the liability of the sponsor, the Principal Investigator and the members of the research team. The cover concerns any injury or disability arising from participation in the study and, in the event of death or permanent incapacity for work, amounts to at least EUR 300,000.00 per subject.

An insurance certificate is uploaded to CTIS, in Greek or in English. During the assessment it is verified that the cover is in force and that the certificate:

- states a study title consistent with the title in Part I, together with the protocol name and code and the EU CT number,
- states the period of insurance cover and the start and end dates of the study,
- covers at least the number of subjects declared for Greece,
- lists all sites with the following details: name and specialty of the Principal Investigator, hospital, clinic or department and full postal address,
- includes the pregnancy clause (see below).

Where the stated period of validity expires before the anticipated completion of the study, which is usually due to the annual renewal of the sponsor's insurance programme, the sponsor ensures continuous cover.

Pregnancy clause: The certificate includes an express provision for cover of the neonate in the event of pregnancy, in the following wording:

"In the event that the participant, or the partner of a participant, becomes pregnant despite the specific and detailed information provided in the protocol and in the informed consent document concerning the risks of the investigational product and the avoidance of pregnancy, and where termination of the pregnancy is not possible for medical or conscientious reasons, if the neonate presents health problems that are attributable to the investigational product or to the procedures required by the protocol, the neonate is covered and insured."

The Greek wording of the clause is set out in C.6 of the Greek version and in the Committee's circular. Either language is accepted.

C.7 Financial and other arrangements

The financial agreement signed by the sponsor and the Principal Investigator does not need to be uploaded to CTIS. So that the Committee is informed of the financial aspects of the study, the following Annexes to Government Gazette B' 230/22.01.2026 are uploaded, duly completed:

- Breakdown of the fee per participating patient (Annex A')
- Members of the Project Team: consolidated list of members (Annex C')
- Project budget: categories of expenditure (Annex D')

The research team documents uploaded to CTIS need not bear the signatures of the sponsor and the investigator.

Cap on the Principal Investigator's remuneration. At no trial site may the remuneration of the Principal Investigator exceed 50% of the sum of the remunerations of all members of the Project Team, that sum including the Principal Investigator's own remuneration; equivalently, the Principal Investigator's remuneration may not exceed the sum of the remunerations of the remaining members. Compliance is verified against Annexes C' and D' and per trial site.

Where compensation of subjects is envisaged, it is recommended that the "Compensation for trial participants" template in EudraLex, Volume 10, Chapter 1 be used, completed in English. As to which benefits are permissible, see B.4.

Committee announcement of 18.03.2025 (see index F.1)

C.8 Compliance with personal data protection law

A statement by the sponsor or an authorised representative concerning the application of Regulation (EU) 2016/679 as regards the processing and transfer of personal data to third countries. The "Statement of compliance with Regulation (EU) 2016/679 (GDPR)" template in EudraLex, Volume 10, Chapter 1 is recommended, completed in English.

C.9 Biological samples

The template "Compliance with Member State applicable rules for the collection, storage and future use of human biological samples (Article 7.1h)" in EudraLex, Volume 10, Chapter 1 is recommended, completed in English, with the questions on collection, storage and future use duly answered.

As to the substantive requirements for future use, see B.6.

C.10 How are personal and commercially confidential data protected within CTIS?

CTIS allows two versions of the same document to be submitted. The "for publication" version is available to the public through the public workspace of the system, and the sponsor is responsible for redacting any personal or commercially confidential data. The "not for publication" version is accessible only to the authorities and contains the full text.

See EudraLex, Volume 10, Chapter V, Questions and Answers on Regulation (EU) No 536/2014, questions 2.9 and 6.5.

PART D: Medical devices and in vitro diagnostics: national specific part

This Part reflects the Committee's document on dossier contents currently in force. As regards compensation of subjects, Article 69 of Regulation (EU) 2017/745 and Article 38 of Law 4931/2022 apply.

D.1 How is the application submitted to the Committee?

Applications for initial conduct and for modifications are submitted electronically, through the registry e-mail address of the National Organisation for Medicines (protokollo@eof.gr), for the attention of the Committee.

Once the relevant online application system becomes operational, the method of submission will be notified by a relevant announcement.

D.2 What does the dossier for an initial opinion contain?

- Cover letter.
- The completed application form in Greek, available on the website of the National Organisation for Medicines, in searchable PDF, signed and dated, with the signatory's details, in Greek and in English.
- Where the sponsor is not the applicant, a letter of authorisation from the sponsor to the applicant.
- Confirmation of receipt of the EUDAMED CIV ID.
- General summary of the clinical investigation or performance study, in Greek.
- The clinical investigation plan or performance study plan, in Greek; English is also accepted.
- Subject information and consent document in Greek; optionally also in English, where the Greek version is a translation of a global version.
- Investigator's Brochure in English, where one exists.
- Agreement between the sponsor and the Principal Investigator on compliance with the protocol.
- Curriculum vitae of the investigator, signed and dated, referring to or evidencing ICH-GCP training.
- Financial agreement with its annexes, for all trial sites, signed by the sponsor and the investigator, in Greek.
- Copy of the detailed budget of the cost, as filed with the competent body.
- Insurance contract for the whole duration of the clinical investigation, from an insurer established within the European Union.

D.3 What applies to substantial modifications?

The dossier is submitted as a single dossier for all trial sites, where the modification concerns all sites, and contains the documents of all sites, except those whose removal has been notified to the Committee.

In every case of modification the following are submitted: a cover letter, the completed standard application form in Greek and in English and, where the sponsor is not the applicant, a letter of authorisation. The additional documents vary according to the request; where the plan or the consent document is amended, the revised version is submitted in clean form and with changes marked.

Where a new trial site is added or the Principal Investigator changes, items 1 to 3 and 9 to 13 of D.2 apply accordingly.

PART E

Procedure before the Committee

E.1 When does the Committee issue requests for information?

A request for information (RFI) is issued where ambiguities, omissions or outstanding matters are identified that require a response from the sponsor.

An RFI is not issued at the sponsor's request in order to allow updated or new documents to be filed. The submission or addition of documents unrelated to the corresponding RFI is not accepted.

Committee announcement of 14.05.2025 (see index F.1)

E.2 When does the Committee meet and how are meetings scheduled?

The Committee holds two ordinary meetings each month, in every month of the year without exception, in accordance with Ministerial Decision G5a/59676/22.12.2016 (Government Gazette B' 4131), and extraordinary meetings whenever required.

Each meeting considers the requests submitted up to one month before the date of the plenary. This information concerns the Committee's internal scheduling and does not alter the assessment timelines laid down by the Regulation.

The schedule of meetings for each year is drawn up in November of the preceding year and is not made public.

Committee announcement of 14.05.2025 (see index F.1)

E.3 How is the outcome of the Part II assessment notified?

The outcome of the Part II assessment is notified by the Part II Assessment Report, which is drawn up in accordance with the template of the Regulation and published in CTIS only. The opinion form used until then was discontinued as of the second ordinary meeting of November 2025 and is no longer issued.

The Report is the sole official document notifying the Committee's final opinion and serves any related documentation needs vis-à-vis third parties. It is distinct from the single decision of the Member State on the application, which covers both Parts.

Committee announcement of 25.11.2025 (see index F.1)

E.4 What are the consequences of a negative opinion?

A negative opinion of the Committee is binding on the National Organisation for Medicines as regards the rejection of the application.

E.5 How are modifications categorised?

The categorisation of changes as substantial modifications, changes under Article 81(9) and non-substantial modifications follows the European Commission's Questions and Answers document on Regulation (EU) No 536/2014 and its annexes, in EudraLex, Volume 10. This document does not reproduce their content.

E.6 How is the Committee's Secretariat contacted?

The Secretariat of the Committee may be contacted by telephone on 213-2040203 and at the e-mail addresses [eed\[at\]eof\[dot\]gr](mailto:eed[at]eof[dot]gr) and [eprountz\[at\]eof\[dot\]gr](mailto:eprountz[at]eof[dot]gr).

Committee announcement of 13.01.2026 (see index F.1)

PART F

Annexes

F.1 Index of Committee announcements

The dates below are those borne by the text of each announcement. The announcements are published in Greek on the website of the National Organisation for Medicines.

Date	Subject	Entry	Link
18.03.2025	Remuneration of the Principal Investigator in a clinical study	C.7	https://www.eof.gr/%ce%b1%ce%bc%ce%bf%ce%b9%ce%b2%ce%ae-%ce%ba%cf%8d%cf%81%ce%b9%ce%bf%cf%85-%ce%b5%cf%81%ce%b5%cf%85%ce%bd%ce%b7%cf%84%ce%ae-%cf%83%ce%b5-%ce%ba%ce%bb%ce%b9%ce%bd%ce%b9%ce%ba%ce%ae-%ce%bc%ce%b5%ce%bb/
05.05.2025	Future use of biological samples	B.6, C.9	https://www.eof.gr/%ce%bc%ce%b5%ce%bb%ce%bb%ce%bf%ce%bd%cf%84%ce%b9%ce%ba%ce%ae-%cf%87%cf%81%ce%ae%cf%83%ce%b7-%ce%b2%ce%b9%ce%bf%ce%bb%ce%bf%ce%b3%ce%b9%ce%ba%cf%8e%ce%bd-%ce%b4%ce%b5%ce%b9%ce%b3%ce%bc%ce%ac%cf%84/
14.05.2025	Clarifications on matters within the Committee's remit	E.1, E.2	https://www.eof.gr/%ce%b4%ce%b9%ce%b5%cf%85%ce%ba%cf%81%ce%b9%ce%bd%ce%af%cf%83%ce%b5%ce%b9%cf%82-%cf%84%ce%b7%cf%82-%ce%b5%ce%b8%ce%bd%ce%b9%ce%ba%ce%ae%cf%82-%ce%b5%cf%80%ce%b9%cf%84%cf%81%ce%bf%cf%80%ce%ae%cf%82/
03.07.2025	Seeking information about subjects	B.5	https://www.eof.gr/%ce%b1%ce%bd%ce%b1%ce%b6%ce%ae%cf%84%ce%b7%cf%83%ce%b7-%cf%80%ce%bb%ce%b7%cf%81%ce%bf%cf%86%ce%bf%cf%81%ce%b9%cf%8e%ce%bd-%ce%b3%ce%b9%ce%b1-%ce%b1%cf%83%ce%b8%ce%b5%ce%bd%ce%b5%ce%af%cf%82/
25.11.2025	Replacement of the opinion form	E.3	https://www.eof.gr/%ce%b1%ce%bd%cf%84%ce%b9%ce%ba%ce%b1%cf%84%ce%ac%cf%83%cf%84%ce%b1%cf%83%ce%b7-%ce%b5%ce%bd%cf%84%cf%8d%cf%80%ce%bf%cf%85-%ce%b3%ce%bd%cf%89%ce%bc%ce%bf%ce%b4%cf%8c%cf%84%ce%b7%cf%83%ce%b7%cf%82/
13.01.2026	Contacting the Secretariat of the Committee	E.6	https://www.eof.gr/%ce%b5%cf%80%ce%b9%ce%ba%ce%bf%ce%b9%ce%bd%cf%89%ce%bd%ce%af%ce%b1-%ce%bc%ce%b5-%cf%84%ce%b7%ce%bd-%ce%b3%cf%81%ce%b1%ce%bc%ce%bc%ce%b1%cf%84%ce%b5%ce%af%ce%b1-%cf%84%ce%b7%cf%82-%ce%b5%ce%b8%ce%bd/

Date	Subject	Entry	Link
22.07.2026	Financial benefits offered to subjects	B.4	https://www.eof.gr/%cf%83%cf%87%ce%b5%cf%84%ce%b9%ce%ba%ce%ac-%ce%bc%ce%b5-%cf%84%ce%b7%ce%bd-%cf%80%cf%81%ce%bf%cf%83%cf%86%ce%bf%cf%81%ce%ac-%ce%bf%ce%b9%ce%ba%ce%bf%ce%bd%ce%bf%ce%bc%ce%b9%ce%ba%cf%8e%ce%bd-%cf%80/

The full web addresses of the announcements are set out in the Greek version of this document.